Efficacy and safety of switching from adalimumab to baricitinib: phase 3 data in patients with rheumatoid arthritis

Similar Items

• Efficacy and safety of switching from adalimumab to baricitinib: Phase 3 data in patients with rheumatoid arthritis
  by: Taylor, P, et al.
  Published: (2016)
• Efficacy and safety of switching from adalimumab to baricitinib: long-term data from phase 3 extension study in patients with rheumatoid arthritis
  by: Weinblatt, M, et al.
  Published: (2018)
• Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis
  by: Tanaka, Y, et al.
  Published: (2019)
• Baricitinib versus placebo or adalimumab in rheumatoid arthritis
  by: Taylor, P, et al.
  Published: (2017)
• Microarray pathway analysis comparing baricitinib and adalimumab in moderate to severe rheumatoid arthritis patients, from a Phase 3 study
  by: Emery, P, et al.
  Published: (2017)